These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 34895133)

  • 1. Preventive treatment with CGRP monoclonal antibodies restores brain stem habituation deficits and excitability to painful stimuli in migraine: results from a prospective case-control study.
    Thiele A; Klehr L; Strauß S; Angermaier A; Schminke U; Kronenbuerger M; Naegel S; Fleischmann R
    J Headache Pain; 2021 Dec; 22(1):149. PubMed ID: 34895133
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of multiple treatment cycles with anti-CGRP monoclonal antibodies on migraine course: focus on discontinuation periods. Insights from the multicenter, prospective, I-GRAINE study.
    Barbanti P; Aurilia C; Egeo G; Proietti S; Torelli P; d'Onofrio F; Carnevale A; Tavani S; Orlando B; Fiorentini G; Colombo B; Filippi M; Bonassi S; Cevoli S;
    J Neurol; 2024 May; 271(5):2605-2614. PubMed ID: 38342785
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Frequency-Dependent Habituation Deficit of the Nociceptive Blink Reflex in Aura With Migraine Headache. Can Migraine Aura Modulate Trigeminal Excitability?
    Perrotta A; Anastasio MG; De Icco R; Coppola G; Ambrosini A; Serrao M; Sandrini G; Pierelli F
    Headache; 2017 Jun; 57(6):887-898. PubMed ID: 28488755
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The monoclonal CGRP-receptor blocking antibody erenumab has different effects on brainstem and cortical sensory-evoked responses.
    Casillo F; Sebastianelli G; Di Renzo A; Cioffi E; Parisi V; Di Lorenzo C; Serrao M; Coppola G
    Cephalalgia; 2022 Oct; 42(11-12):1236-1245. PubMed ID: 35637558
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deterioration of headache impact and health-related quality of life in migraine patients after cessation of preventive treatment with CGRP(-receptor) antibodies.
    Terhart M; Mecklenburg J; Neeb L; Overeem LH; Siebert A; Steinicke M; Raffaelli B; Reuter U
    J Headache Pain; 2021 Dec; 22(1):158. PubMed ID: 34972502
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The blink reflex in "chronic migraine".
    De Marinis M; Pujia A; Colaizzo E; Accornero N
    Clin Neurophysiol; 2007 Feb; 118(2):457-63. PubMed ID: 17141567
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A ketogenic diet normalizes interictal cortical but not subcortical responsivity in migraineurs.
    Di Lorenzo C; Coppola G; Bracaglia M; Di Lenola D; Sirianni G; Rossi P; Di Lorenzo G; Parisi V; Serrao M; Cervenka MC; Pierelli F
    BMC Neurol; 2019 Jun; 19(1):136. PubMed ID: 31228957
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-calcitonin gene-related peptide monoclonal antibodies for neuropathic pain in patients with migraine headache.
    Kang SA; Govindarajan R
    Muscle Nerve; 2021 Apr; 63(4):563-567. PubMed ID: 33347632
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Migraine induction with calcitonin gene-related peptide in patients from erenumab trials.
    Christensen CE; Younis S; Deen M; Khan S; Ghanizada H; Ashina M
    J Headache Pain; 2018 Nov; 19(1):105. PubMed ID: 30409109
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nociceptive blink reflex and visual evoked potential habituations are correlated in migraine.
    Di Clemente L; Coppola G; Magis D; Fumal A; De Pasqua V; Schoenen J
    Headache; 2005; 45(10):1388-93. PubMed ID: 16324171
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improvement of migraine depressive symptoms is not related to headache frequency: exploring the impact of anti-CGRP therapies.
    Torres-Ferrús M; Gallardo VJ; Alpuente A; Caronna E; Giné-Ciprés E; Pozo-Rosich P
    Cephalalgia; 2024 Feb; 44(2):3331024231222923. PubMed ID: 38307497
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of anti-CGRP monoclonal antibodies in resistant migraine patients: a real-world evidence observational study.
    Torres-Ferrús M; Gallardo VJ; Alpuente A; Caronna E; Gine-Cipres E; Pozo-Rosich P
    J Neurol; 2021 Oct; 268(10):3789-3798. PubMed ID: 33772636
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical evaluation of super-responders vs. non-responders to CGRP(-receptor) monoclonal antibodies: a real-world experience.
    Raffaelli B; Fitzek M; Overeem LH; Storch E; Terhart M; Reuter U
    J Headache Pain; 2023 Feb; 24(1):16. PubMed ID: 36843007
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discontinuing monoclonal antibodies targeting CGRP pathway after one-year treatment: an observational longitudinal cohort study.
    Vernieri F; Brunelli N; Messina R; Costa CM; Colombo B; Torelli P; Quintana S; Cevoli S; Favoni V; d'Onofrio F; Egeo G; Rao R; Filippi M; Barbanti P; Altamura C
    J Headache Pain; 2021 Dec; 22(1):154. PubMed ID: 34922444
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The efficacy and safety of calcitonin gene-related peptide monoclonal antibody for episodic migraine: a meta-analysis.
    Zhu Y; Liu Y; Zhao J; Han Q; Liu L; Shen X
    Neurol Sci; 2018 Dec; 39(12):2097-2106. PubMed ID: 30182284
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Habituation of the nociceptive blink reflex in episodic and chronic cluster headache.
    Holle D; Zillessen S; Gaul C; Naegel S; Kaube H; Diener HC; Katsarava Z; Obermann M
    Cephalalgia; 2012 Oct; 32(13):998-1004. PubMed ID: 22807570
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CGRP, a target for preventive therapy in migraine and cluster headache: Systematic review of clinical data.
    Khan S; Olesen A; Ashina M
    Cephalalgia; 2019 Mar; 39(3):374-389. PubMed ID: 29110503
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Switching anti-CGRP(R) monoclonal antibodies in multi-assessed non-responder patients and implications for ineffectiveness criteria: A retrospective cohort study.
    Iannone LF; Burgalassi A; Vigani G; Tabasso G; De Cesaris F; Chiarugi A; Geppetti P
    Cephalalgia; 2023 Apr; 43(4):3331024231160519. PubMed ID: 36918752
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Calcitonin gene-related peptide (CGRP) and migraine current understanding and state of development.
    Bigal ME; Walter S; Rapoport AM
    Headache; 2013 Sep; 53(8):1230-44. PubMed ID: 23848260
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peripherally acting anti-CGRP monoclonal antibodies alter cortical gray matter thickness in migraine patients: A prospective cohort study.
    Szabo E; Ashina S; Melo-Carrillo A; Bolo NR; Borsook D; Burstein R
    Neuroimage Clin; 2023; 40():103531. PubMed ID: 37866119
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.